While revolutionary, its limitations include cardiotoxicity and resistance, addressed partly by biosimilars like Ogivri and Kanjinti, as biosimilars of trastuzumab, are used to treat HER2-positive breast and gastric cancers by inhibiting tumour growth [60]. Here, ERBB2 is linked to neoplasm.